Narrow search
Showing 1 - 10 of 9,871
Cover Image
Compulsory licensing : implications on multinational drug companies
Prasad, Vure; Babu, P. S. S. Krishna - In: International journal of intellectual property … 6 (2013) 4, pp. 247-271
Persistent link: https://www.econbiz.de/10010252986
Cover Image
Designing pro-health competition policies in developing countries
Ido, Vitor Henrique Pinto - 2020
Persistent link: https://www.econbiz.de/10012433548
Cover Image
Implications of Indian IP policy on patenting activity of pharmaceutical multinational corporations in India
Venkataraman, P.; Bhagwat, Gauri; Deshpande, Vasanti; … - In: International journal of intellectual property … 8 (2015) 3/4, pp. 249-266
Persistent link: https://www.econbiz.de/10011549498
Cover Image
The TRIPS agreement and the pharmaceutical industry in India
Kamiike, Atsuko - In: Journal of interdisciplinary economics 32 (2020) 1, pp. 95-113
Persistent link: https://www.econbiz.de/10012161217
Cover Image
Harmonization of intellectual property rights across the globe : impact on India's pharmaceutical exports
Bhandarkar, Supriya - 2020
Persistent link: https://www.econbiz.de/10012518985
Cover Image
Pharmaceutical Patents and Expropriation in Indian Bilateral Investment Treaties
Ranjan, Prabhash - 2017
This chapter discusses whether foreign investors, specifically pharmaceutical companies, could challenge India …'s regulatory measures that impact their patents under India's BITs. More specifically, the paper will focus on whether regulatory … expropriation under India's bilateral investment treaties (BITs). The discussion in the chapter shows that pharmaceutical patents …
Persistent link: https://www.econbiz.de/10012959457
Cover Image
Big pharma and monopoly capitalism: a long-term view
Dosi, Giovanni; Marengo, Luigi; Staccioli, Jacopo; … - 2021
Are IPRs institutions meant to foster innovative activities or conversely to secure appropriation and profitability? Taking stock of a long-term empirical evidence on the pharmaceutical sector in the US, we can hardly support IPRs intended as an innovation rewarding institution. According to our...
Persistent link: https://www.econbiz.de/10012604733
Cover Image
Access to medicines after TRIPS : is compulsory licensing an effective mechanism to lower drug prices? ; a review of the existing evidence
Urias, Eduardo; Ramani, Shyama V. - In: Journal of International Business Policy : JIBP 3 (2020) 4, pp. 367-384
Persistent link: https://www.econbiz.de/10012405471
Cover Image
Recognizing public goods in WTO dispute settlement : who participates? Who decides? The case of TRIPS and pharmaceutical patent protection
Shaffer, Gregory C. - In: International public goods and transfer of technology …, (pp. 884-908). 2005
Persistent link: https://www.econbiz.de/10003415336